In broad general terms, the main strategies for new AD drug treatments are:
Antibodies
Numerous anti-amyloid antibodies are in clinical development and are designed to reduce brain amyloid burden.
Secretase Inhibitors
Using drugs to decrease the amyloid burden by inhibiting the enzymes responsible for the generation of the A-beta peptide from its precursor protein APP.
Targeting Amyloid Aggregation
Another strategy has been to test drugs that block the downstream consolidation of soluble A-beta oligomers into insoluble aggregates and plaques.
Alternatively, drugs might preventing interaction between A-beta with metals in the synapse which leads to the formation of small toxic oligomers of A-beta that inhibit neurotransmission.
Antibodies
Numerous anti-amyloid antibodies are in clinical development and are designed to reduce brain amyloid burden.
Secretase Inhibitors
Using drugs to decrease the amyloid burden by inhibiting the enzymes responsible for the generation of the A-beta peptide from its precursor protein APP.
Targeting Amyloid Aggregation
Another strategy has been to test drugs that block the downstream consolidation of soluble A-beta oligomers into insoluble aggregates and plaques.
Alternatively, drugs might preventing interaction between A-beta with metals in the synapse which leads to the formation of small toxic oligomers of A-beta that inhibit neurotransmission.